Lyell Immunopharma Inc (LYEL)

Currency in USD
24.000
-0.810(-3.26%)
Closed·
24.0000.000(0.00%)
·
LYEL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
23.00025.050
52 wk Range
7.65045.000
Key Statistics
Prev. Close
24.81
Open
24.52
Day's Range
23-25.05
52 wk Range
7.65-45
Volume
75.38K
Average Volume (3m)
82.29K
1-Year Change
103.2865%
Book Value / Share
17.13
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LYEL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
29.667
Upside
+23.61%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Lyell Immunopharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Lyell Immunopharma Inc Company Profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Compare LYEL to Peers and Sector

Metrics to compare
LYEL
Peers
Sector
Relationship
P/E Ratio
−1.6x−2.3x−0.6x
PEG Ratio
0.050.010.00
Price/Book
1.5x2.4x2.6x
Price / LTM Sales
12,435.5x9.4x3.4x
Upside (Analyst Target)
29.0%356.6%44.9%
Fair Value Upside
Unlock26.0%6.7%Unlock

Analyst Ratings

2 Buy
0 Hold
1 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 29.667
(+23.61% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy45.00+87.50%20.00UpgradeDec 09, 2025
Lucid Capital Markets
Buy20.00-16.67%-New CoverageSep 26, 2025
H.C. Wainwright
Hold10.00-58.33%1.00MaintainJun 24, 2025
H.C. Wainwright
Hold1.00-95.83%-MaintainMar 13, 2025

Earnings

Latest Release
Nov 12, 2025
EPS / Forecast
-2.13 / -0.1664
Revenue / Forecast
15.00K / --
EPS Revisions
Last 90 days

LYEL Income Statement

People Also Watch

18.99
BIOA
-0.58%
18.37
ZBIO
-12.02%
52.60
AFJK
+0.21%
10.510
ERAS
+1.94%
8.01
KYTX
-2.44%

FAQ

What Is the Lyell Immunopharma (LYEL) Stock Price Today?

The Lyell Immunopharma stock price today is 24.000

What Stock Exchange Does Lyell Immunopharma Trade On?

Lyell Immunopharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Lyell Immunopharma?

The stock symbol for Lyell Immunopharma is "LYEL."

What Is the Lyell Immunopharma Market Cap?

As of today, Lyell Immunopharma market cap is 509.85M.

What Is Lyell Immunopharma's Earnings Per Share (TTM)?

The Lyell Immunopharma EPS (TTM) is -21.06.

From a Technical Analysis Perspective, Is LYEL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Lyell Immunopharma Stock Split?

Lyell Immunopharma has split 1 times.

How Many Employees Does Lyell Immunopharma Have?

Lyell Immunopharma has 300 employees.

What is the current trading status of Lyell Immunopharma (LYEL)?

As of Jan 31, 2026, Lyell Immunopharma (LYEL) is trading at a price of 24.000, with a previous close of 24.810. The stock has fluctuated within a day range of 23.000 to 25.050, while its 52-week range spans from 7.650 to 45.000.

What Is Lyell Immunopharma (LYEL) Price Target According to Analysts?

The average 12-month price target for Lyell Immunopharma is USD29.667, with a high estimate of USD45 and a low estimate of USD12. 2 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +23.61% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.